MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Core Viewpoint - MiNK Therapeutics, Inc. has been selected for an oral presentation at the AACR IO Annual Meeting, showcasing interim data from its Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for treating refractory gastric cancer [1][2]. Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [1][2]. - The company is advancing a pipeline of both native and engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [2]. Product Information - AgenT-797 is an allogeneic iNKT cell therapy that combines the cytotoxic capabilities of natural killer cells with the adaptive memory of T cells, allowing for a broad range of immune responses [3]. - The product is designed to be a scalable, "off-the-shelf" cell therapy, manufactured in Lexington, MA [4]. Presentation Details - The oral presentation will focus on biomarker analysis from the Phase 2 study of AgenT-797 in combination with botensilimab and balstilimab for PD-1 refractory gastroesophageal cancer [2]. - The presentation is scheduled for February 25, 2025, from 1:00 to 1:45 p.m. PST [2].